Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis.

ABSTRACT: Changes in serum sodium concentration ([Na⁺]_serum) can permit evaluation of the treatment effect of vasopressin antagonists (vaptans) in patients with worsening heart failure (HF) or cirrhotic ascites; that is, they may act as a treatment stratification biomarker. A two-stage systematic review and meta-analysis were carried out and contextualized by experts in fluid resuscitation and translational pharmacology (registration ID in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42017051440). Meta-analysis of aggregated dichotomous outcomes was performed. Pooled estimates for correction of hyponatremia (normalization or an increase in [Na⁺]_serum of at least 3⁻5 mEq/L) under treatment with vaptans (Stage 1) and for clinical outcomes in both wo

SUBMITTER: Herrera-Gomez F 

PROVIDER: S-EPMC6162844 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature